Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Target
Cadrenal Therapeutics, Inc. Common Stock · NASDAQ
$1.53-0.04 (-2.55%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Cadrenal Therapeutics, Inc. Common Stock, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $13.00 to $13.00, so the covering firms are broadly aligned. The average target of $13.00 sits 750% above the current $1.53. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.88 next quarter toward $-3.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Cadrenal Therapeutics, Inc. Common Stock.
As of Aug, 1 of 1 firms rate CVKD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CVKD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.88
Range $-0.89 – $-0.87 · 2 analysts · -38% YoY
Next period, 2 analysts expect Cadrenal Therapeutics, Inc. Common Stock to earn $-0.88 a share (range $-0.89 – $-0.87), versus $-1.41 a year earlier. Full-year consensus is $-3.92, growing to $-3.40 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Cadrenal Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CVKD.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #298
Buy
$13.00+749.7% to target
Overall win rate
33%
+ Follow
CVKD stock forecast FAQ
What is CVKD's average 12-month price target?+
The 1 analysts with a live target average $13.00 for Cadrenal Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $13.00 high to a $13.00 low.
Is CVKD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CVKD?+
1 analysts have an active rating on Cadrenal Therapeutics, Inc. Common Stock, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering CVKD?+
Among analysts who currently cover CVKD, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #298). Their current call is Buy with a $13.00 target.
What is Cadrenal Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.88 per share (range $-0.89 – $-0.87) across 2 analysts. Full-year EPS is projected at $-3.92, rising to $-3.40 the following year.
How much revenue is Cadrenal Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CVKD lately?+
As of Aug, 1 of 1 firms rate CVKD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CVKD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
